The eCTD requirement for promotional materials means promotional submissions travel the same road as every other electronic submission: through the FDA Electronic Submissions Gateway. For a company already filing INDs and NDAs electronically, that is a non-event — the gateway is there, the certificates work, the acknowledgements route.
For a newly commercial-stage company whose first-ever gateway submission is a 2253, it is not a non-event at all. It is three separate lead times stacked on top of each other, and they are usually discovered in the wrong order — after a piece has already been approved for dissemination.
The three lead times
- An ESG account — a multi-step process with FDA that must be started well before your first electronic submission
- A successful test submission — FDA requires new gateway users to complete one before production use, validating connectivity, certificate configuration and acknowledgement routing
- OPDP’s structural review — a separate, optional but strongly advisable process in which the OPDP project management team reviews your promotional submission structure and tells you what is wrong with it
The third is the one people do not know exists. It is not the same as the ESG test submission, it is run by a different team, and it addresses a different failure class — the gateway test proves you can transmit, and the OPDP review proves you have assembled a promotional submission correctly.
Choosing WebTrader or AS2
Submissions reach the ESG one of two ways.
| WebTrader | AS2 gateway-to-gateway | |
|---|---|---|
| What it is | A web portal — log in, digitally sign, submit, view agency responses | A system-to-system connection exchanging submissions with FDA |
| Designed for | Lower-volume submitters | Higher volume and automation |
| What you must run | Nothing beyond a browser and credentials | Gateway software on your side |
| Trade-off | Manual, per-submission human effort | Setup and maintenance burden, but transmission can be driven by a system |
Promotional submissions are the use case that most often changes this decision. A company filing four sequences a year is comfortably a WebTrader shop. The same company running an active promotional programme — where each piece, each revision and each campaign wave generates a submission tied to a dissemination date — can find its volume an order of magnitude higher, and entirely manual transmission becomes the bottleneck.
It is worth sizing that honestly before choosing, because migrating from WebTrader to AS2 later is its own project.
Getting an account
The first step toward submitting electronically is to request a test account. For AS2 specifically, the registration URL and a temporary login can be obtained from the FDA ESG administrator by emailing the ESG help desk to indicate your intent to register.
After the test account is issued and the required centre-compliant test is completed, you receive user authentication credentials for production, and submissions can be sent to the gateway for delivery onward to the centres.
The recurring advice from FDA — and it is worth repeating because it is the single most common planning error — is that this should be started well before you intend to make your first submission. Certificate issuance, account provisioning and a successful test are not same-week activities.
OPDP’s test submission process
Separately from the gateway test, OPDP runs a structural review for promotional submissions. It exists precisely so submitters can validate eCTD structure before hitting the production environment, and the OPDP project management team provides feedback and correction instructions.
The process runs roughly like this:
- Review the available presentations on the OPDP eCTD page and prepare your questions
- Contact the OPDP eCTD mailbox with your questions, the submission types you intend to use — 2253, advisory, accelerated approval — and your availability for a short planning meeting
- OPDP schedules a planning meeting, answers the questions and helps you plan test cases
- You submit the test files, then notify the mailbox of the result — accepted or rejected — providing the COR ID when accepted
- OPDP reviews the test submission and gives feedback
For an organisation about to begin promotional submissions, this is a structural review of your work by the people who will receive the real thing, at no cost. Given that a single reused sequence number will reject an entire grouped submission, and that a misplaced application list silently under-distributes a group, it is difficult to justify skipping it.
Sequencing the whole thing
If you are standing this capability up from nothing, the order that avoids the most pain is:
- Now: request the ESG test account; decide WebTrader versus AS2 based on realistic promotional volume, not current filing volume
- In parallel: work through the OPDP eCTD material and draft your submission structure for each type you will use
- Before any material is approved for dissemination: complete the ESG test, then run the OPDP structural review
- Only then: let the first real dissemination date be set
The failure that this ordering prevents is the common one: a launch date fixed by commercial, a piece approved through MLR, and a regulatory operations team discovering with days to spare that the gateway account does not exist yet. The obligation is contemporaneous with dissemination, so there is no slack in which to fix it.
Primary sources
- FDA ESG submission process
- Setting up a WebTrader account — checklist
- ESG Chapter 5 — AS2 gateway-to-gateway submissions
- OPDP eCTD page — presentations and the eCTD mailbox for the test submission process
DnXT builds eCTD publishing, validation and dossier review software for regulatory operations teams. This article is general information about FDA requirements, not regulatory advice — verify every detail against the current FDA guidance and forms before you rely on it.
